



All Sites and Facilities

## Sotrovimab Infusion Orders (For COVID-19 Only)

Page 1 of 2

Last Name:			
First Name (Preferred Name):			
Encounter number:	NH Number:	Chart Created: Yes/ No	
Date of Birth:	Gender:	Age:	Encounter Type:
Responsibility for Payment:		PHN:	
Primary Care Physician/Attending Physician:			
<b>PATIENT LABEL</b>			

Allergies:  None Known     Unable to Obtain  
List with Reactions: \_\_\_\_\_

Weight: \_\_\_\_\_ kg  
Height: \_\_\_\_\_ cm

*Note: follow infection control procedures for COVID-19 in all settings.  
Please fax completed orders to pharmacy*

- 1. CONSULT:** Refer to NH Firstline (app.firstline.org) for step-by-step eligibility guide for mild to moderate COVID-19 patients. For pregnant patients contact the reproductive ID specialist on-call at BC Women's Hospital: 604-875-2161.
- 2. INCLUSION CRITERIA:** for patients NOT eligible for **nirmatrelvir-ritonavir** (Paxlovid), **sotrovimab** may be considered in confirmed, mildly-ill COVID-19 patients (e.g. no supplemental oxygen), 18 years or older who are:
  - outpatients or hospitalized for non-COVID-19 related reasons (e.g. medical/surgical indications)
  - within 7 days of symptom onset**\*AND\* one of the following:**
  - inadequate immune response to COVID-19 vaccine or high-risk conditions regardless of vaccine status (see page 2)
  - unimmunized and either 50 years or older **\*OR\*** have three or more chronic conditions listed below
  - partially immunized and 50 years or older with three or more chronic conditions listed below
  - partially immunized and 70 years or older with one or more chronic conditions listed below
  - self-identify as Indigenous (e.g. First Nations [including status and non-status], Inuit, or Métis)Chronic conditions that increase risk for developing severe COVID-19-related complications:

<input type="checkbox"/> hypertension/heart disease	<input type="checkbox"/> stroke
<input type="checkbox"/> chronic kidney disease	<input type="checkbox"/> neurological conditions
<input type="checkbox"/> COPD	<input type="checkbox"/> obesity (BMI greater than 30)
<input type="checkbox"/> diabetes	<input type="checkbox"/> smoking

### 3. EXCLUSION CRITERIA

Do NOT use **sotrovimab** if any of the following:

- symptoms consistent with severe COVID-19 defined by shortness of breath at rest or respiratory distress and requiring supplemental oxygen
- presenting greater than 7 days from symptom onset or life expectancy of less than 7 days
- intravenous immunoglobulin use during current admission
- receipt of convalescent plasma or monoclonal antibody for COVID-19 within last 3 months

### 4. MONITORING

- **Initial:** temp, BP, HR, RR and SpO<sub>2</sub> prior to infusion then q15 minutes during infusion x 2 then q30 minutes until end of infusion
- **Post-Infusion:** temp, BP, HR, RR, SpO<sub>2</sub> and other infusion-related reactions q30 minutes x 1 hour after infusion complete
- Notify MRP of infusion-related reactions

### 5. MEDICATIONS

#### A. PRN medications

- acetaminophen** 650 mg PO/NG/PR x 1 dose PRN for infusion-related reaction
- diphenhydramine** 50 mg PO/IV x 1 dose PRN for infusion-related reaction
- dimenhydrinate** 50 mg PO/IV x 1 dose PRN for infusion-related reaction
- methylprednisolone sodium succinate** 125 mg IV x 1 dose PRN for infusion-related reaction

#### B. Intermittent Infusion Order

- **sotrovimab** 500 mg IV once x 1 dose. Infuse over 60 minutes.

Prescriber signature: \_\_\_\_\_ College ID: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_

10-800-5021 (IND - RDPO/VPM - Rev. - 03/22) Review by December 2024

~ Do NOT photocopy or alter electronically. Print new copies directly from OurNH Order Set Site ~



**Sotrovimab Infusion Orders**  
**(For COVID-19 Only)**

Last Name:			
First Name (Preferred Name):			
Encounter number:	NH Number:	Chart Created: Yes/ No	
Date of Birth:	Gender:	Age:	Encounter Type:
Responsibility for Payment:		PHN:	
Primary Care Physician/Attending Physician:			
<i>PATIENT LABEL</i>			

**Patients who may have had an inadequate response to vaccination despite full vaccination for COVID-19 (any of the following):**

- active treatment for solid tumor or hematological malignancies
- having received a solid organ transplant and treated with immunosuppression
- receiving CAR-T cell therapy or hematopoietic stem cell transplant in the last 2 years
- having a moderate to severe primary immunodeficiency
- having advanced untreated HIV or AIDS
- active receipt of anti-B cell therapies (e.g. **riTUXimab**, **ocrelizumab**, **obinutuzumab**), high-dose systemic steroids (= 20 mg **prednisone** equivalent daily for at least 14 days), alkylating agents (e.g. **cyclophosphamide**, **CISplatin**), antimetabolites (e.g. **methotrexate**, **fluorouracil**) or anti-TNF agents (e.g. **inFLIXimab**, **adalimumab**)

**High-risk conditions regardless of vaccine status:**

- 70 years or older with three or more chronic conditions (e.g. obesity, diabetes, heart failure stroke, neurological conditions)
- cystic fibrosis, insulin-dependent diabetes, severe asthma or COPD, blood disorders (e.g. sickle cell, thalassemia), rare metabolic disorders (e.g. urea cycle defects), splenectomy, pregnant with serious heart disease, significant development disorders (e.g. Cerebral Palsy), or neurological/other conditions causing significant muscle weakness around lungs